Autoimmune diseases such as lupus and rheumatoid arthritis (RA) are associated with significant increase in mortality compared to the general population, mainly driven by excess atherosclerosis and cardiovascular disease (CVD). The increased CV risk in RA for example is comparable to CV risk seen in patients with type II diabetes mellitus. Conditions such as scleroderma demonstrate primary myocardial involvement that are a leading cause of morbidity and mortality.
To reduce cardiovascular (CV) co-morbidity in patients with autoimmune and musculoskeletal conditions.
We deliver a multi-disciplinary and multi-technology investigative approach, using well-defined clinical cohorts to understand the risks and shared mechanisms of autoimmune disease and CVD, in order to deliver tailored pathways of care and improve CV outcomes of patients with autoimmune and MSK conditions. By investigating the model of autoimmune disease, its therapeutics and CVD we can also enable knowledge transfer to the general coronary artery disease (CAD) population.
In patients with autoimmune and MSK conditions:
The research programme is delivered by the cardiovascular pathology in autoimmune disease (CARDIO-AID) group comprising clinical academics in rheumatology and cardiovascular and metabolic medicine, laboratory scientists and medical physicists; capitalising on expertise in imaging, inflammation and immunology research.
This collaboration comprises two of the strategic areas within the School of Medicine and is aligned with the priority areas for LTHT (Musculoskeletal and Cardiovascular) and its R&I strategy.